亚洲国产精品一区二区久久hs,精品国产一级在线观看,免 费 成人黄 色 大片,不卡中文一二三区,国产剧情麻豆mv在线观看,久久久久久久久久久精品,久久九九综合,久久久久久91香蕉国产

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購(gòu)物車 1 種商品 - 共0元
當(dāng)前位置: 首頁(yè) > ATCC代理 > DC101
▍最近瀏覽歷史
▍聯(lián)系我們
  • 0574-87157013
  • mingzhoubio@163.com
  • 浙江省寧波市鎮(zhèn)海區(qū)莊市街道興莊路9號(hào)
  • 創(chuàng)e慧谷42號(hào)樓B幢401室
DC101
DC101
規(guī)格:
貨期:
編號(hào):B164339
品牌:Mingzhoubio

標(biāo)準(zhǔn)菌株
定量菌液
DNA
RNA

規(guī)格:
凍干粉
斜面
甘油
平板


產(chǎn)品名稱 DC101
商品貨號(hào) B164339
Organism Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma)
Tissue
Spleen
Cell Type hybridoma
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Strain Lewis (B cell); BALB/c (myeloma)
Applications
DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.
Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization
Storage Conditions liquid nitrogen vapor phase
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Animals were hyperimmunized with an immune complex consisting of the mouse FLK-1:SEAPs soluble receptor, a rabbit anti-alkaline phosphatase polyclonal antibody and Protein-G sepharose beads.
Spleen cells were fused with NS-1 mouse myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against murine vascular endothelial growth factor (VEGF) receptor-2 (Flk-1/KDR)
Cellular Products
immunoglobulin; monoclonal antibody; against murine vascular endothelial growth factor (VEGF) receptor-2 (Flk-1/KDR)
Comments
DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.
DC101 does not cross-react with the human VEGFR2/KDR.
Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium 92.5%; DMSO, 7.5%
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain
Name of Depositor ImClone Systems Inc.
Deposited As rat (B cell); mouse (myeloma)
U.S. Patent Number
References

Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 5,955,311 dated Sep 21 1999

Witte L, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17: 155-161, 1998. PubMed: 9770111

Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59: 5209-5218, 1999. PubMed: 10537299

Shaheen RM, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 18: 221-226, 2001. PubMed: 11172585

Kadambi A, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61: 2404-2408, 2001. PubMed: 11289105

Kozin SV, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61: 39-44, 2001. PubMed: 11196192

Zimmermann RC, et al. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc. Res. 62: 15-25, 2001. PubMed: 11421657

Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15-R24, 2000. PubMed: 10772661

Stoelcker B, et al. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J. Inferon Cytokine Res. 20: 511-517, 2000. PubMed: 10841080

梅經(jīng)理 17280875617 1438578920
胡經(jīng)理 13345964880 2438244627
周經(jīng)理 17757487661 1296385441
于經(jīng)理 18067160830 2088210172
沈經(jīng)理 19548299266 2662369050
李經(jīng)理 13626845108 972239479
尤溪县| 赞皇县| 阿坝| 阳朔县| 宁安市| 西丰县| 礼泉县| 陇南市| 云龙县| 天气| 长乐市| 肥城市| 桐柏县| 崇左市| 故城县| 芦山县| 鱼台县| 周至县| 鄄城县| 保德县| 哈巴河县| 永年县| 东丽区| 民和| 娄底市| 怀来县| 彭泽县| 安宁市| 汽车| 利津县| 沐川县| 永昌县| 青神县| 万全县| 古蔺县| 平武县| 四平市| 五华县| 太白县| 灵台县| 罗田县|